Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Enhancement of drug delivery through fibroblast activation protein–targeted near-infrared photoimmunotherapy
Seitaro Nishimura, Kazuhiro Noma, Tasuku Matsumoto, Yasushige Takeda, Tatsuya Takahashi, Hijiri Matsumoto, Kento Kawasaki, Hotaka Kawai, Tomoyoshi Kunitomo, Masaaki Akai, Teruki Kobayashi, Noriyuki Nishiwaki, Hajime Kashima, Takuya Kato, Satoru Kikuchi, Shunsuke Tanabe, Toshiaki Ohara, Hiroshi Tazawa, Yasuhiro Shirakawa, Peter L. Choyke, Hisataka Kobayashi, Toshiyoshi Fujiwara
Seitaro Nishimura, Kazuhiro Noma, Tasuku Matsumoto, Yasushige Takeda, Tatsuya Takahashi, Hijiri Matsumoto, Kento Kawasaki, Hotaka Kawai, Tomoyoshi Kunitomo, Masaaki Akai, Teruki Kobayashi, Noriyuki Nishiwaki, Hajime Kashima, Takuya Kato, Satoru Kikuchi, Shunsuke Tanabe, Toshiaki Ohara, Hiroshi Tazawa, Yasuhiro Shirakawa, Peter L. Choyke, Hisataka Kobayashi, Toshiyoshi Fujiwara
View: Text | PDF
Research Article Gastroenterology Oncology

Enhancement of drug delivery through fibroblast activation protein–targeted near-infrared photoimmunotherapy

  • Text
  • PDF
Abstract

The tumor microenvironment plays a key role in cancer progression and therapy resistance, with cancer-associated fibroblasts (CAFs) contributing to desmoplasia, extracellular matrix (ECM) remodeling, and elevated interstitial fluid pressure, all of which hinder drug delivery. We investigated fibroblast activation protein–targeted (FAP-targeted) near-infrared photoimmunotherapy (NIR-PIT) as a strategy to improve drug penetration in CAF-rich tumors. In clinical esophageal cancer samples, FAP expression strongly correlated with increased collagen I, hyaluronic acid, and microvascular collapse. CAF-rich 3D spheroids demonstrated elevated ECM deposition and significantly impaired drug uptake compared with CAF-poor models. FAP-targeted NIR-PIT selectively reduced CAFs, reduced ECM components, and restored drug permeability. In vivo, FAP-targeted NIR-PIT enhanced the accumulation of panitumumab and Abraxane in CAF-rich tumors and improved antitumor efficacy when combined with chemotherapy. These findings highlight FAP-targeted NIR-PIT as a promising therapeutic approach to remodel the tumor stroma and overcome drug resistance in desmoplastic solid tumors.

Authors

Seitaro Nishimura, Kazuhiro Noma, Tasuku Matsumoto, Yasushige Takeda, Tatsuya Takahashi, Hijiri Matsumoto, Kento Kawasaki, Hotaka Kawai, Tomoyoshi Kunitomo, Masaaki Akai, Teruki Kobayashi, Noriyuki Nishiwaki, Hajime Kashima, Takuya Kato, Satoru Kikuchi, Shunsuke Tanabe, Toshiaki Ohara, Hiroshi Tazawa, Yasuhiro Shirakawa, Peter L. Choyke, Hisataka Kobayashi, Toshiyoshi Fujiwara

×

Figure 8

In vivo synergistic antitumor effects of FAP-targeted NIR-PIT combined with Abraxane.

Options: View larger image (or click on image) Download as PowerPoint
In vivo synergistic antitumor effects of FAP-targeted NIR-PIT combined w...
CAF-rich tumors (human TE8 cells cocultured with human FEF3 cells at a 1:3 ratio) were used throughout this figure. (A) Fluorescent images of PI staining in TE8 cells, untreated (control) or treated with Abra-IR800. Abra-IR800, green; PI, red. Original magnification, ×200 (scale bars: 100 μm). (B) Quantitative analysis of PI-positive cell counts in untreated (control) and Abra-IR800–treated cells (n = 3; mean ± SEM; unpaired t test). (C) Diagram of treatment protocol and NIR light application. (D) Tumor growth curve in mice injected with Sib-IR700, with or without NIR light exposure (n = 5; mean ± SEM; 1-way ANOVA with Tukey’s test). (E) Comparison of tumor weights between right-side tumors exposed to NIR light and left-side tumors without NIR light in Sib-IR700–injected mice (n = 5; ratio paired t test). (F) IHC images showing αSMA, Masson’s trichrome staining, and CD31 in tumors treated with Sib-IR700, with or without NIR light. αSMA and Masson’s trichrome staining, original magnification ×200 (scale bars: 100 μm); CD31, original magnification ×400 (scale bars: 50 μm). (G) Quantitative comparison of αSMA and Masson’s trichrome staining areas, as well as MVD of vessels at least 10 μm in diameter, in tumors treated with Sib-IR700 without versus with NIR light (n = 5; ratio paired t test). Statistical significance: *P < 0.05; **P < 0.01; ****P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts